带有 C 末端组氨酸标签的 N501Y 变体

NR-55417?? Spike Glycoprotein S1 Domain from SARS-Related Coronavirus 2, N501Y Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein S1 Domain from SARS-Related Coronavirus 2, N501Y Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells|-20°C or colder|ACROBiosystemsAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein S1 Domain from SARS-Related Coronavirus 2, N501Y Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55417.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein S1 domain from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), N501Y variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55417 lacks the signal sequence, contains 670 residues of the SARS-CoV-2 S glycoprotein (amino acid residues V16 to R685) and features a C-terminal poly-histidine tag. NR-55417 is a variant of SARS-CoV-2 which contains the N501Y mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55417 has a theoretical molecular weight of 76,900 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. New SARS-CoV-2 mutations in the S glycoprotein are currently under study, and a B.1.1.7 lineage (also known as 20B/501Y.V1, VOC202012/01 or United Kingdom variant) and a B.1.351 lineage (also known as 20C/501Y.V2 or South Africa variant) include the N501Y mutation. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. The biological activity of NR-55417 was measured by its binding ability in a functional ELISA, in which immobilized NR-55417 at 2 ?g per mL (100 ?L per well) can bind human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257); the linear range is 0.1 to 3 ng per mL. Immobilized NR-55417 at 2 ?g per mL (100 ?L per well) can bind Anti-SARS-CoV-2 RBD neutralizing antibody (ACROBiosystems SAD-S35); the linear range is 0.1 to 3 ng per mL. Immobilized NR-55417 at 2 ?g per mL (100 ?L per well) can bind biotinylated human ACE2/ACEH His, Avitag? protein (ACROBiosystems AC2-H82E6); the linear range is 0.1 to 3 ng per mL. Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose. Additional information and tools are available at ViPR (Virus Pathogen Resource).

NR-55413?? Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, N501Y Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, N501Y Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells|-20°C or colder|ACROBiosystemsAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, N501Y Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55413.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), N501Y variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55413 lacks the signal sequence, contains 219 residues of the SARS-CoV-2 S glycoprotein (amino acid residues R319 to K537) and features a C-terminal poly-histidine tag. NR-55413 is a variant of SARS-CoV-2 which contains the N501Y mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55413 has a theoretical molecular weight of 26,600 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. Many SARS-CoV-2 variants include multiple mutations that were first identified in the United Kingdom, and the most studied is N501Y. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. The biological activity of NR-55413 was measured by its binding ability in a functional ELISA, in which immobilized human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257) at 1 ?g per mL (100 ?L per well) can bind NR-55413; the linear range is 2 to 39 ng per mL. Immobilized NR-55413 at 1 ?g per mL (100 ?L per well) can bind anti-SARS-CoV-2 RBD potent neutralizing antibody, human IgG1 (ACROBiosystems SPD-M180); the linear range is 0.1 to 3 ng per mL. Serial dilutions of SPD-M180 were added to NR-55413 and biotinylated human ACE2, His, Avitag? (ACROBiosystems AC2-H82E6) binding reactions. The half maximal inhibitory concentration (IC₅₀) is 1.13169 ?g per mL. Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose. Additional information and tools are available at ViPR (Virus Pathogen Resource).